(-0.23%) 5 024.23 points
(0.33%) 37 939 points
(-0.28%) 15 615 points
(-3.06%) $79.42
(-2.71%) $1.937
(0.69%) $2 318.70
(0.63%) $26.82
(1.69%) $964.25
(-0.09%) $0.936
(-0.18%) $11.08
(0.07%) $0.801
(-0.05%) $93.40
Live Chart Being Loaded With Signals
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe...
Stats | |
---|---|
今日成交量 | 17 399.00 |
平均成交量 | 99 631.00 |
市值 | 359.25M |
下一个收益日期 | ( $0 ) 2024-06-03 |
Last Dividend | $0.300 ( 2023-11-21 ) |
Next Dividend | $0 ( N/A ) |
P/E | 16.63 |
ATR14 | $0.0160 (0.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-30 | Saba Capital Management, L.p. | Buy | 16 573 | Common Stock |
2024-04-26 | Saba Capital Management, L.p. | Buy | 120 304 | Common Stock |
2024-04-25 | Saba Capital Management, L.p. | Buy | 97 574 | Common Stock |
2024-04-24 | Saba Capital Management, L.p. | Buy | 20 529 | Common Stock |
2024-04-23 | Saba Capital Management, L.p. | Buy | 48 203 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 58 transactions |
Buy: 554 423 | Sell: 55 759 |
音量 相关性
Tekla Life Sciences 相关性 - 货币/商品
Tekla Life Sciences 财务报表
Annual | 2023 |
营收: | $23.52M |
毛利润: | $18.28M (77.71 %) |
EPS: | $0.830 |
FY | 2023 |
营收: | $23.52M |
毛利润: | $18.28M (77.71 %) |
EPS: | $0.830 |
FY | 2022 |
营收: | $-103.25M |
毛利润: | $-108.80M (105.37 %) |
EPS: | $-4.07 |
FY | 2021 |
营收: | $65.69M |
毛利润: | $0.00 (0.00 %) |
EPS: | $2.78 |
Financial Reports:
No articles found.
Tekla Life Sciences Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.310 (N/A) |
$0.310 (N/A) |
$0.330 (N/A) |
$0.320 (N/A) |
$0.320 (N/A) |
$0.300 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $1.640 | 1996-11-14 |
Last Dividend | $0.300 | 2023-11-21 |
Next Dividend | $0 | N/A |
Payout Date | 2024-01-10 | |
Next Payout Date | N/A | |
# dividends | 99 | -- |
Total Paid Out | $43.17 | -- |
Avg. Dividend % Per Year | 5.54% | -- |
Score | 5.04 | -- |
Div. Sustainability Score | 1.232 | |
Div.Growth Potential Score | 1.007 | |
Div. Directional Score | 1.119 | -- |
Year | Amount | Yield |
---|---|---|
1996 | $1.640 | 10.80% |
1997 | $0.740 | 5.38% |
1998 | $0.360 | 2.76% |
1999 | $1.110 | 9.06% |
2000 | $4.16 | 20.50% |
2001 | $3.14 | 14.90% |
2002 | $2.18 | 10.20% |
2003 | $1.240 | 10.10% |
2004 | $1.365 | 8.62% |
2005 | $2.06 | 13.00% |
2006 | $1.240 | 7.90% |
2007 | $1.170 | 8.74% |
2008 | $1.100 | 8.33% |
2009 | $0.420 | 4.59% |
2010 | $0.520 | 5.46% |
2011 | $1.010 | 9.29% |
2012 | $1.160 | 10.00% |
2013 | $1.390 | 9.19% |
2014 | $1.770 | 8.72% |
2015 | $2.80 | 11.20% |
2016 | $2.07 | 8.99% |
2017 | $1.620 | 9.38% |
2018 | $1.620 | 8.18% |
2019 | $1.400 | 9.03% |
2020 | $1.560 | 8.98% |
2021 | $1.690 | 8.71% |
2022 | $1.360 | 7.05% |
2023 | $1.270 | 8.87% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
NCZ | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.79% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
SJT | Dividend Royal | 2023-11-29 | Monthly | 39 | 12.52% | 8.50 |
SRV | Dividend Royal | 2023-12-04 | Monthly | 18 | 7.53% | 8.50 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
GOF | Dividend Royal | 2023-11-14 | Monthly | 18 | 8.03% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.568 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0556 | 1.200 | 8.15 | 9.78 | [0 - 0.3] |
returnOnEquityTTM | 0.0813 | 1.500 | -0.207 | -0.311 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.0000000 | 2.00 | 0.0000000 | 0.0000000 | [0 - 30] |
freeCashFlowPerShareTTM | 0.0000000 | 2.00 | 0.0000000 | 0.0000000 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.867 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.568 | 1.000 | 0.649 | 0.649 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.0978 | 0.800 | -2.68 | -2.14 | [0.5 - 2] |
Total Score | 1.232 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 15.67 | 1.000 | 8.52 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0813 | 2.50 | -0.133 | -0.311 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.0000000 | 2.00 | 0.0000000 | 0.0000000 | [0 - 30] |
dividendYielPercentageTTM | 10.17 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.0000000 | 2.00 | 0.0000000 | 0.0000000 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0619 | 1.500 | -3.75 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0000000 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | 1.007 |
Tekla Life Sciences
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。